TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

23 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022

12 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe

01 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

11 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Virtual Investor Event

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

03 Nov 2022 09:34:04 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

05 Oct 2022 08:33:23 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in Upcoming Investor Conferences

22 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

10 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

03 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology

11 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer

07 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire